FDA-approved
Digestive & weight
Liraglutide
Evidence
FDA approved
Class
GLP-1 receptor agonist
KEY TAKEAWAY
Liraglutide is a modified version of human GLP-1 that lasts about a day in the body. It is sold as Victoza for diabetes and Saxenda for weight management. The FDA approved liraglutide (Victoza) in 2010 for type 2 diabetes and a higher-dose version (Saxenda) in 2014 for weight management. Generic versions are now available.
Written by the Veylo editorial team · Updated
November 2026
What it is
GLP-1 receptor agonist
Approved for
Type 2 diabetes and chronic weight management
Key fact
The FDA approved liraglutide (Victoza) in 2010 for type 2 diabetes and a higher-dose version (Saxenda) in 2014 for weight management. Generic versions are now available.
Route
Daily subcutaneous injection
Evidence strength
FDA approved
Liraglutide is a modified version of human GLP-1 that lasts about a day in the body. It is sold as Victoza for diabetes and Saxenda for weight management.
It activates GLP-1 receptors, which raises insulin release when blood sugar is high, slows stomach emptying and reduces appetite.
The FDA approved liraglutide (Victoza) in 2010 for type 2 diabetes and a higher-dose version (Saxenda) in 2014 for weight management. Generic versions are now available.
Type 2 diabetes and chronic weight management.
Nausea, vomiting and diarrhea are the most common effects. The label carries a boxed warning about thyroid C-cell tumors seen in rodents, and pancreatitis and gallbladder disease are possible.
U.S. FDA prescribing information for Liraglutide. DailyMed, National Library of Medicine.
Veylo content is educational and not medical advice. Peptides that are not FDA-approved are not approved for the uses described.